New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 12, 2013
07:13 EDTZIOPZiopharm trial reaches target number of progression-free survival events
ZIOPHARM Oncology announced that the Phase 3, PICASSO 3, trial of palifosfamide in first-line metastatic soft tissue sarcoma has reached its target number of progression-free survival events. PICASSO 3 is an international, randomized, double-blind, placebo-controlled trial whose primary endpoint is PFS. According to the protocol and statistical plan, reaching the target number of PFS events leads to completion of the blinded data collection process and then formal efficacy analysis by the Independent Data Monitoring Committee. The company will announce topline results from this trial during the last week of March, it said. The company said, "Reaching the target number of progression events for PICASSO 3 positions us one step closer to understanding palifosfamide's full potential for this significant unmet medical need. With a positive study outcome, palifosfamide has the potential to become the first new treatment option in nearly 30 years for patients with first-line metastatic soft tissue sarcoma."
News For ZIOP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 29, 2015
10:48 EDTZIOPOptions with increasing implied volatility
Subscribe for More Information
September 28, 2015
16:04 EDTZIOPIntrexon to collaborate with Ziopharm for graft-versus-host disease
Intrexon (XON) announced it has formed a new exclusive channel collaboration with Ziopharm Oncology (ZIOP) for the treatment and prevention of graft-versus-host disease. The collaboration will focus on addressing the underlying pathologies of GvHD through engineered cell platforms to express and deliver interleukin-2. The companies plan to pursue engineered cell therapy strategies, used either separately or in combination, for targeted treatment of GvHD. The first approach is infusion of regulatory T cells conditionally expressing IL-2 utilizing Intrexon's proprietary gene control approaches such as its RheoSwitch platform. The second is deployment of orally-delivered microbe-based ActoBiotics therapeutics expressing IL-2 to modulate immune function. Under the terms of the agreement, Intrexon will receive a technology access fee of $10M in cash and reimbursement for all research and development costs. The agreement also provides for equal sharing of operating profits.
07:14 EDTZIOPZIOPHARM names Eagle Pharmaceuticals CEO to board
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use